CORRECTED-AstraZeneca to sell US rights for gout drug for up to $265 mln
April 26, 2016 at 05:17 AM EDT
April 26 (Reuters) - British drugmaker AstraZeneca Plc said Ironwood Pharmaceuticals Inc would buy the U.S. marketing rights for its newly-approved gout drug for up to $265 million.